SBIR/STTR Research Award

The development of FastMyco™ : A novel isothermal colorimetric assay for the rapid detection of mycoplasma contamination .

Award identifier 1597020064a5a76cf93a61cf84323dde482bf6c15364b437e2d607f784ad67edAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$274,324

Program and phase

SBIR · Phase I

Award year

2020

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AMELIA TECHNOLOGIES LLC
Proposal award date
2020-09-01
Contract end date
2021-02-28
UEI
H1EQZ5W49ZV3
Solicitation number
PA19-272
Topic code
300

Research abstract

SBIR 2020: 6823823214: The development of FastMyco™: A novel isothermal colorimetric assay for the rapid detection of mycoplasma contamination. The development of FastMyco™: A novel isothermal colorimetric assay for the rapid detectionof mycoplasma contamination. Project Summary/ Abstract(Word Count: 350) Mycoplasma (myco) contamination of mammalian cell lines are recognized as a major contributor to the lack of reproducibility in modern biomedical research. Despite the availability of commercially marketed detection systems, the unabated prevalence of myco in research attests to the shortcomings of these protocols. Indeed, all currently marketed myco tests fail to address the actual needs of the consumer, the bench scientist. For a myco detection product to be widely adopted it must: 1) require no additional equipment or infrastructure, 2) integrate seamlessly into a laboratory’s daily tissue culture routine with no additional labor burden on the users, and 3) be sensitive, inexpensive, and yield results immediately. To this end, in Phase I of this proposal we will optimize the FastMyco™ assay to test cell-culture media samples. FastMyco™ uses breakthrough Recombinase Polymerase Amplification (RPA) coupled to an initial reverse transcriptase (RT) step (RT-RPA), resulting in an all-in-one isothermal alternative to PCR myco detection. In FastMyco™, the RT-RPA reaction will target the 16S rRNA of myco, with amplification conducted in the cell-culture incubator at 37°C for approx. 15- 20 minutes. The assay has a potential detection limit of less than 1 CFU/ ml and immediate colorimetric output from an onboard detection system. The thermal stability of the system is a major technical and cost advantage of FastMyco™ over comparable systems. This will be achieved using cutting-edge lyophilization techniques that will create a multi-layered bead containing all necessary enzymes and reagents, freeze-dried around a core of DNA-detection substrate. The bead dissolves at different rates releasing the detection reagent only after target amplification has begun. In Phase II, we will continue to develop FastMyco™ for large HTP research organizations but also expand the bead-based detection systems to other human and agricultural pathogens. We will strive to integrate FastMyco™ into every laboratory’s routine cell-culture. The assay would also give regulatory agencies such as NIH and FDA the leverage to require this more rigorous testing protocols to help curb the spread of mycoplasma in research.SBIR 2020: 6823823214: The development of FastMyco™: A novel isothermal colorimetric assay for the rapid detection of mycoplasma contamination. NARRATIVE The cost and extent of mycoplasma contamination is enormous, and prevalent in all sectors of biological, agricultural and medical research. The prevalence of contamination is indicative of the ineffectiveness of current mycoplasma detection protocols. In Phase I research, we will continue to develop FastMyco™, the only detection assay that needs no additional time or equipment. FastMyco™, uses isothermal amplification of RNA with onboard detection to give the user a result in less than 20 minutes at a fraction (~10%) of the price per sample of other competitor assays. The strength of FastMyco™ is the ability to be used in any cell culture facility and integrated seamlessly, into the routine cell maintenance activities. In Phase II, FastMyco™ will be further developed into a generic diagnostic test platform, able to be used in the field or in remote locations to detect selected viral or bacterial pathogens.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

9 SBIR/STTR records share this UEI (2018–2025). Reported award amounts total $7,698,439. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.